In the ORIGIN trial and the DEVOTE trial, both enrolled patients with T2DM with ASCVD or at high cardiovascular risk, demonstrated no significant difference in the primary composite outcomes between insulin glargine vs standard care or insulin degludec vs insulin glargine U100 (Table 2; Bosch et al., 2012; Marso et al., 2017). Here, INS is linked to type 2 diabetes mellitus.